The Situation has Changed–For the Better?
Insidevaccines will be posting occasional news stories related to vaccines with commentary by our team of editors. Here we go–
In 2002 Robert Goldberg wrote:
Despite significant activity in the area of vaccine design, vaccinology and immunology, vaccine development is on the verge of becoming a brackish backwater of other biotechnology and pharmaceutical enterprises. The market for vaccines is dominated by government purchasers that drive prices down to commodity levels, the regulations for the development and production of new vaccines are mired in the 1950s and sometimes cost more than producing vaccines themselves.
Public health officials and politicians are — depending on the day — either indifferent or outright hostile to the [sic] providing private companies with incentives for investing in new vaccines for a wide range of diseases. Indeed the solution de jour is to have the government — perhaps the Department of Defense (DOD) or some offshoot of the public health service — take over the development and production of vaccines, as if a U.S. government run National Vaccine Authority could magically and efficiently construct and operate billion dollar facilities without any glitches or major disruptions. Only scientists whose only brush with business is food shopping could concoct such an idiotic scheme.
Only a few years later and vaccines are spraying out of the pipeline and into babies, children, teens, and adults at an amazing rate. I guess the government listened to industry and we will all benefit. After all, there is just no limit to the number of vaccines the human body can absorb…is there?
March 17, 2008 07:43 AM Eastern Daylight Time
VacZine Analytics: Number of Available Vaccines Set to Double by 2015
LONDON–(BUSINESS WIRE)–
…number of available vaccines in major Western markets could double by 2015 to 75-80 products
….
With the success of its new Human Papillomavirus (HPV) quadrivalent vaccine Gardasil, Merck & Co experienced the fastest growth between 2006-07 reporting $4.2 bn of revenue in 2007 although GlaxoSmithKline and Sanofi Pasteur closely follow. Like Gardasil over the next few years many new vaccines are predicted to achieve blockbuster status (>$1 bn revenue) such as those for meningitis serogroups B and ACWY and pnuemococcal infections.
…focused on supporting key business franchises such as influenza, meningitis and pediatric combinations.
….
For example, new vaccines are being developed to prevent hospital infections caused by MRSA, Clostridium difficile and Psuedomonas aureginosa. Other vaccines are focused on serious infections in the newborn such as group B Streptococcus (GBS), respiratory syncytial virus (RSV) and cytomegalovirus (CMV).
Warm thanks to Vaccination News for offering up thousands of vaccination article links over many years.
Comments
Tell me what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!